View Filing Data

Document and Entity Information Document - USD ($)	3 Months Ended
Document and Entity Information Document - USD ($)	Mar. 31, 2014	May 08, 2014	Jun. 30, 2013
Document Information [Line Items]
Entity Registrant Name	NeoStem, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		34,008,862
Entity Public Float			$ 92,300,000

Consolidated Balance Sheets - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 41,359,652	$ 46,133,759
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively	1,887,558	1,860,835
Inventory	1,475,812	1,270,223
Prepaid expenses and other current assets	1,833,082	1,561,933
Total current assets	46,556,104	50,826,750
Property, plant and equipment, net	13,790,672	12,844,216
Goodwill	11,117,770	11,117,770
Intangible assets, net	13,724,314	13,875,617
Other assets	1,204,765	1,151,729
Assets, Total	86,393,625	89,816,082
Current Liabilities
Accounts payable	3,296,078	3,354,908
Accrued liabilities	2,381,625	4,018,026
Notes payable	836,219	381,097
Mortgages payable	216,005	213,112
Derivative Liabilities, Current	23,175	23,175
Unearned revenues	2,033,116	1,816,601
Total current liabilities	8,786,218	9,806,919
Long-term Liabilities
Deferred income taxes	4,426,635	4,379,226
Notes payable	870,864	531,164
Secured Long-term Debt, Noncurrent	2,967,948	3,023,609
Business Combination, Contingent Consideration, Liability	9,640,000	9,450,000
Other long-term liabilities	635,008	598,729
Total liabilities	27,326,673	27,789,647
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 1/100 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2014 and December 31, 2013	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 28,593,410 and 27,196,537 shares, at March 31, 2014 and December 31, 2013, respectively	28,594	27,197
Additional paid-in capital	310,377,112	299,594,525
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(250,055,662)	(236,373,605)
Total NeoStem, Inc. stockholders' equity	59,644,402	62,542,475
Noncontrolling interests	(577,450)	(516,040)
Total equity	59,066,952	62,026,435
Liabilities and Equity, Total	$ 86,393,625	$ 89,816,082

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Accounts receivable trade, net of allowance for doubtful accounts	$ 390,118	$ 391,829
Preferred Stock, authorized	20,000,000	20,000,000
Common stock, outstanding	28,593,410	27,196,537
Common Stock, authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	28,593,410	27,196,537
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value	$ 0.01	$ 0.01

Consolidated Statements of Operations - USD ($)	3 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Revenues	$ 4,055,575	$ 2,523,912
Cost of revenues	3,825,444	2,392,089
Research and development	4,759,083	3,161,326
Selling, general, and administrative	8,970,016	5,801,872
Total operating costs and expenses	17,554,543	11,355,287
Operating loss	(13,498,968)	(8,831,375)
Other income (expense):
Other income (expense), net	(189,551)	10,606
Interest expense	(94,156)	(43,560)
Nonoperating Income (Expense), Total	(283,707)	(32,954)
Loss before provision for income taxes and noncontrolling interests	(13,782,675)	(8,864,329)
Provision for income taxes	47,409	0
Net loss	(13,830,084)	(8,864,329)
Less - loss attributable to noncontrolling interests	(148,027)	(63,754)
Net Income (Loss) Available to Common Stockholders, Basic	(13,682,057)	(8,800,575)
Amounts Attributable to NeoStem, Inc. common stockholders:
Net Income (Loss) Available to Common Stockholders, Basic	$ (13,682,057)	$ (8,800,575)
Basic and diluted (loss) per share attributable to NeoStem, Inc. common stockholders:
NeoStem, Inc. common stockholders	$ (0.49)	$ (0.53)
Weighted average common shares outstanding	28,120,847	16,698,897

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Net loss	$ (13,830,084)	$ (8,864,329)
Total other comprehensive (loss) income	0	0
Comprehensive loss	(13,830,084)	(8,864,329)
Comprehensive loss attributable to noncontrolling interests	(148,027)	(63,754)
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	$ (13,682,057)	$ (8,800,575)

Consolidated Statements of Equity - USD ($)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Noncontrolling Interest [Member]
Beginning Balance (shares) at Dec. 31, 2012		10,000	16,375,365
Beginning Balance at Dec. 31, 2012	$ 32,820,159	$ 100	$ 16,375	$ 231,218,615	$ 0	$ (197,392,361)	$ (665,600)	$ 33,177,129	$ (356,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,864,329)					(8,800,575)		(8,800,575)	(63,754)
Share-based compensation (in shares)			177,492
Share-based compensation	2,218,530		$ 178	2,218,352				2,218,530
Net proceeds from issuance of common stock (in shares)			454,254
Net proceeds from issuance of common stock	2,730,263		$ 455	2,729,808				2,730,263
Proceeds from Stock Options Exercised	0
Proceeds from warrant exercise (in shares)			20,761
Proceeds from exercise of warrants	105,881		$ 21	105,860				105,881
Warrant Inducements (in shares)			0
Warrant Inducements			$ 0	(6,239)				(6,239)
Adjustments to Additional Paid in Capital, Warrant Issued	(6,239)
Ending Balance at Mar. 31, 2013	29,004,265	$ 100	$ 17,029	236,266,396	0	(206,192,936)	(665,600)	29,424,989	(420,724)
Ending Balance (shares) at Mar. 31, 2013		10,000	17,027,872
Beginning Balance (shares) at Dec. 31, 2013		10,000	27,196,537
Beginning Balance at Dec. 31, 2013	62,026,435	$ 100	$ 27,197	299,594,525	0	(236,373,605)	(705,742)	62,542,475	(516,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(13,830,084)					(13,682,057)		(13,682,057)	(148,027)
Share-based compensation (in shares)			329,698
Share-based compensation	3,893,616		$ 330	3,893,286			0	3,893,616
Net proceeds from issuance of common stock (in shares)			804,375
Net proceeds from issuance of common stock	5,630,625		$ 804	5,629,821				5,630,625
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			12,800
Proceeds from Stock Options Exercised	71,360		$ 13	71,347				71,360
Proceeds from warrant exercise (in shares)			250,000
Proceeds from exercise of warrants	1,275,000		$ 250	1,274,750				1,275,000
Change in Ownership in Subsidiary	0		0	(86,617)				(86,617)	86,617
Ending Balance at Mar. 31, 2014	$ 59,066,952	$ 100	$ 28,594	$ 310,377,112	$ 0	$ (250,055,662)	$ (705,742)	$ 59,644,402	$ (577,450)
Ending Balance (shares) at Mar. 31, 2014		10,000	28,593,410

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (13,830,084)	$ (8,864,329)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	3,893,616	2,218,530
Depreciation and amortization	444,452	554,954
Changes in fair value of derivative liability	0	10,606
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	190,000	0
Bad debt recovery	(1,711)	0
Deferred Income Taxes	47,409	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(271,149)	(192,009)
Accounts receivable	(25,012)	167,444
Inventory	(205,589)	(428,549)
Unearned revenues	216,515	346,912
Other assets	(53,035)	(22,986)
Accounts payable, accrued expenses and other liabilities	(1,658,952)	(905,094)
Net cash used in operating activities	(11,253,540)	(7,135,733)
Cash flows from investing activities:
Acquisition of property and equipment	(1,239,606)	(53,571)
Net cash used in investing activities	(1,239,606)	(53,571)
Cash flows from financing activities:
Proceeds from Stock Options Exercised	71,360	0
Proceeds from exercise of warrants	1,275,000	105,881
Net proceeds from issuance of common stock	5,630,625	2,730,262
Repayment of mortgage loan	(52,768)	(43,446)
Proceeds from notes payable	958,014	0
Repayment of notes payable	(163,192)	(81,015)
Change in warrant liabilities	0	(6,239)
Net cash provided by financing activities	7,719,039	2,705,443
Net decrease in cash and cash equivalents	(4,774,107)	(4,483,861)
Cash and cash equivalents at beginning of period	46,133,759	13,737,452
Cash and cash equivalents at end of period	41,359,652	9,253,591
Cash and cash equivalents of continuing operations at end of period	41,359,652
Cash paid during the period for:
Interest	93,100	95,700
Taxes	$ 0	$ 0

The Business

3 Months Ended

Mar. 31, 2014

The Business [Abstract]

Nature of Operations [Text Block]

The Business

Overview

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy platforms that work to address the pathology of disease using a person's own cells to amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.

Our business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that we leverage for the development of our therapeutics while providing service to other companies in the cell therapy industry developing products. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 through the issuance of equity of California Stem Cell, Inc. ("CSC"), a cell biotechnology corporation that is developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. CSC, now known as NeoStem Oncology, LLC, is driving the Company's Targeted Immunotherapy Program for cancer through the development of its lead product candidate, Melapuldencel-T, to treat Stage IV or recurrent melanoma. The Phase 3 protocol is the subject of a Special Protocol Assessment (SPA), indicating that the Food and Drug Administration ("FDA") is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that will serve as the basis for a Biologics License Application ("BLA"). This protocol calls for enrolling 250 patients and is expected to be initiated in 2014.

We are currently developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With the last patient of the planned 160 patient trial infused in late December 2013, we expect the last patient six-month follow-up to occur in June 2014. Once the primary end point six-month data is collected, the data set will be locked and analysis will begin with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to advance the technology into other clinical indications such as chronic heart failure ("CHF"), traumatic brain injury ("TBI"), and/or critical limb ischemia ("CLI").

Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system. In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigen exposure. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, and in allergic diseases, like asthma, the immune system overreacts to harmless foreign substances. We plan to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

Pre-clinical assets include our VSEL^TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall healthcare costs. We are working on a Department of Defense funded study of VSELs^TM for the treatment of chronic wounds. Other preclinical work with VSELs^TMincludes exploring macular degeneration as a target indication.

Progenitor Cell Therapy, LLC ("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, which we acquired in 2011, is an industry leader in providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. Additionally, with the acquisition of CSC, PCT can leverage CSC's additional manufacturing capacity in Irvine, California as well as the personnel experience and expertise in immunotherapy to provide additional manufacturing and /or development work to advance NeoStem's platform technology as well as technologies of PCT's client base.

Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to provide value to stockholders by taking advantage of the infrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding Melapuldencel-T, a late stage novel proprietary cancer cell therapy into our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our best in class manufacturing capability, the stage is set for us to realize meaningful clinical development and manufacturing efficiencies, further positioning NeoStem to lead the cell therapy industry.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2014 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2013 and 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2013. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three months ended March 31, 2013 to conform to the presentation for the three months ended March 31, 2014.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	90%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC (2)	100%	United States of America

(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of March 31, 2014, BD's ownership interest in Athelos was decreased to 10.0%, and our ownership increased to 90.0%. As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.

(2) On May 8, 2014, NeoStem acquired CSC, now known as NeoStem Oncology, LLC (see Note 15, Subsequent Events). Accordingly, the accounts of NeoStem Oncology, LLC are not included in the Company's consolidated financial position as of March 31, 2014 and the results of its consolidated operations and cash flows for the three months ended March 31, 2014 and 2013.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no changes during the three months ended March 31, 2014.

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Inventories

The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Goodwill and Other Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with it's accounting policy, the Company tested goodwill and indefinite-lived intangible assets for impairment as of December 31, 2013 and 2012 for its two reporting units, and concluded there was no risk of failing step 1 of the goodwill impairment testing evaluation, and that indefinite-lived intangible assets were not impaired.

Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSEL™ Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended March 31, 2014 and 2013, clinical services reimbursements were $0.7 million and $0.4 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Cash and Cash Equivalents	3 Months Ended
Cash and Cash Equivalents	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Text Block]	Cash and Cash Equivalents As of March 31, 2014 and December 31, 2013, the Company had cash and cash equivalents of approximately $41.4 million and $46.1 million, respectively, including bank deposits of approximately $0.7 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

Inventories	3 Months Ended
Inventories	Mar. 31, 2014
Inventories [Abstract]
Inventory Disclosure [Text Block]	Inventories Inventories, representing work in process for costs incurred on projects at PCT that have not been completed, were $1.5 million and $1.3 million as of March 31, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $1.6 million and $1.5 million of advance billings received as of March 31, 2014 and December 31, 2013, respectively, related to these contracts.

Loss Per Share

3 Months Ended

Mar. 31, 2014

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the three months ended March 31, 2014 and 2013, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At March 31, 2014 and 2013, the Company excluded the following potentially dilutive securities:



	March 31,
	2014	2013
Stock Options	3,912,697	2,631,181
Warrants	4,491,028	5,501,055
Restricted Shares	175,731	35,500

Fair Value Measurements

3 Months Ended

Mar. 31, 2014

Fair Value Measurements [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company determined the fair value of the warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows.

Contingent consideration was recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte. The contingent consideration obligations relates to earn out payments equal to 10% of the net sales of Amorcyte’s lead product candidate AMR-001 (in the event of and following the date of first commercial sale of AMR-001), provided that in the event NeoStem sublicenses AMR-001, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”).

The fair value of contingent consideration obligations is determined using Level 3 inputs, and is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $9.6 million as of March 31, 2014. The change in estimated fair value is based the impact of the time progression through the Phase 2 clinical trial from December 31, 2013 to March 31, 2014.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014, and December 31, 2013 (in thousands):



	March 31, 2014
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	23.2
Acquisition-related contingent consideration	—		—		9,640.0



	December 31, 2013
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	23.2
Acquisition-related contingent consideration	—		—		9,450.0

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2014 by type of instrument (in thousands):



	Three Months Ended
	March 31, 2014
	Warrants		Acquisition-Related Contingent Consideration
Beginning liability balance	$	23.2	$	9,450.0
Change in fair value recorded in earnings	—		190.0
Ending liability balance	$	23.2	$	9,640.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2014

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The Company's goodwill was $11.1 million as of March 31, 2014 and December 31, 2013.

The Company's intangible assets and related accumulated amortization as of March 31, 2014 and December 31, 2013 consisted of the following (in thousands):



		March 31, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(320.1	)	$	679.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,248.4		)	2,651.6		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(256.1		)	543.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	9,400.0		—			9,400.0		9,400.0		—			9,400.0
VSEL patent rights	19 years	669.0		(220.1		)	448.9		669.0		(211.3		)	457.7
Total Intangible Assets		$	15,769.0	$	(2,044.7	)	$	13,724.3	$	15,769.0	$	(1,893.4	)	$	13,875.6

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2014		2013
Cost of revenue	$	79.2	$	97.5
Research and development	27.1		8.8
Selling, general and administrative	45.0		45.0
Total	$	151.3	$	151.3

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	453.9
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	10,849.6
	$	13,724.3

Accrued Liabilities

3 Months Ended

Mar. 31, 2014

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):



	March 31, 2014		December 31, 2013
Salaries, employee benefits and related taxes	$	846.4	$	2,325.8
Professional fees	775.4		544.8
License Fees	200.0		500.0
Other	559.8		647.4
	$	2,381.6	$	4,018.0

Debt	3 Months Ended
Debt	Mar. 31, 2014
Debt [Abstract]
Debt Disclosure [Text Block]	Debt Notes Payable As of March 31, 2014 and December 31, 2013, the Company had notes payable of approximately $1.7 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years. Mortgages Payable In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The First Mortgage is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The First Mortgage is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The First Mortgage had previously been subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. The outstanding balance was approximately $2.4 million and 2.5 million at March 31, 2014 and December 31, 2013, respectively, of which $128,300 is payable within twelve months as of March 31, 2014. In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage had been subject to an annual financial covenant starting December 31, 2011. The Second Mortgage is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.7 million and $0.8 million at March 31, 2014 and December 31, 2013, respectively, of which $87,700 is payable within twelve months as of March 31, 2014. In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A., whereby (i) prior debt service coverage and total debt to tangible net worth financial covenant ratios were replaced with a minimum unencumbered liquidity covenant, and (ii) prior guarantors were released (see Note 13) and replaced with NeoStem, PCT, and NeoStem Family Storage. The Company is in compliance with the new minimum unencumbered liquidity covenant.

Shareholders' Equity

3 Months Ended

Mar. 31, 2014

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Reverse Stock Split

On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Equity Issuances

In September 2011, the Company entered into a common stock purchase agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement.

In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock was based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we are obligated to issue 150,000 shares of our common stock to Aspire Capital (the “Commitment Shares”).

Option Exercises

During the three months ended ended March 31, 2014, option holders exercised an aggregate of 12,800 options at at exercise prices between of $5.20 and $6.20 per share for gross proceeds of approximately $0.1 million.

Warrant Exercises

During the three months ended ended March 31, 2014, warrant holders exercised an aggregate of 250,000 warrants at an exercise price of $5.10 per share for gross proceeds of approximately $1.3 million.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0

Changes during the Period:
Granted	1,169,200		$	7.70				2,722		$	12.26
Exercised	(12,800	)	$	5.58				(250,000	)	$	5.10
Forfeited	(109,329	)	$	6.97				(100,108	)	$	70.00
Expired	(66,565	)	$	14.77				(59,852	)	$	57.76
Outstanding at March 31, 2014	3,912,697		$	10.22	7.4	$	1,896.7	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46	7.2	$	1,848.9	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014	2,520,755		$	11.50	6.5	$	1,600.9	4,473,306		$	15.42	2.3	$	1,661.5

During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		3,913
Value of Common Stock Purchase Warrants Issued	$	—	$	14.9

Restricted Stock

During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Restricted Stock Issued	329,698		177,492
Value of Restricted Stock Issued	$	2,511.7	$	1,127.9

The weighted average estimated fair value of restricted stock issued for services in the three months ended March 31, 2014 and 2013 was $7.62 and $6.35 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation (Notes)

3 Months Ended

Mar. 31, 2014

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2014 and 2013 (in thousands):



	Three Months Ended March 31,
	2014		2013
Cost of goods sold	$	138.1	$	86.4
Research and development	476.8		217.4
Selling, general and administrative	3,278.7		1,914.7
Total share-based compensation expense	$	3,893.6	$	2,218.5

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at March 31, 2014 were as follows (dollars in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	6,490.0	$	46.2	$	208.2
Expected weighted-average period in years of compensation cost to be recognized	5.62		1.30		0.35

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2014 and 2013 were as follows (dollars in thousands):



	Stock Options				Warrants
	Three Months Ended March 31,				Three Months Ended March 31,
	2014		2013		2014		2013
Total fair value of shares vested	$	1,927.4	$	1,305.0	$	8.7	$	43.8
Weighted average estimated fair value of shares granted	$	5.47	$	4.71	$	—	$	3.82

Income Taxes

3 Months Ended

Mar. 31, 2014

Income Taxes [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Reverse Stock Split

Equity Issuances

Option Exercises

Warrant Exercises

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0

Changes during the Period:
Granted	1,169,200		$	7.70				2,722		$	12.26
Exercised	(12,800	)	$	5.58				(250,000	)	$	5.10
Forfeited	(109,329	)	$	6.97				(100,108	)	$	70.00
Expired	(66,565	)	$	14.77				(59,852	)	$	57.76
Outstanding at March 31, 2014	3,912,697		$	10.22	7.4	$	1,896.7	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46	7.2	$	1,848.9	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014	2,520,755		$	11.50	6.5	$	1,600.9	4,473,306		$	15.42	2.3	$	1,661.5

During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		3,913
Value of Common Stock Purchase Warrants Issued	$	—	$	14.9

Restricted Stock

During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Restricted Stock Issued	329,698		177,492
Value of Restricted Stock Issued	$	2,511.7	$	1,127.9

Income Tax Disclosure [Text Block]

Income Taxes

As of December 31, 2013, the Company had approximately $110.6 million of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2033.

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

Deferred tax liabilities were $4.4 million and $4.4 million as of March 31, 2014 and December 31, 2013, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011, and the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset.

As of March 31, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

- Definition

+ References

+ Details

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	Related Party Transactions In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 9). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Commitments and Contingencies

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for additional space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future and shall extend through 2018. This property is used as the Company's corporate headquarters.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2014 are as follows (in thousands):



Years ended	Operating Leases
2014	$	763.0
2015	840.4
2016	682.3
2017	386.9
2018	5.9
Total minimum lease payments	$	2,678.5

Expense incurred under operating leases was approximately $0.2 million and $0.3 million for the three months ended March 31, 2014 and 2013, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

Subsequent Events

3 Months Ended

Mar. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Subsequent Events

California Stem Cell Acquisition

On May 8, 2014 (the “Closing”), NeoStem closed its acquisition (the “CSC Acquisition”) of CSC, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem, CSC, NBS Acquisition Sub I, Inc., a Delaware corporation and a wholly-owned subsidiary of NeoStem (“Subco”), NBS Acquisition Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of NeoStem (“Subco II”), and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”).

Pursuant to the Merger Agreement, on the Closing Date, (1) Subco was merged with and into CSC (the “First Merger”) and (2) CSC was then merged with and into Subco II (the “Second Merger”, and collectively with the First Merger, the “Mergers”), with Subco II surviving the Mergers as a wholly-owned subsidiary of NeoStem. At Closing, Subco II changed its legal name to NeoStem Oncology, LLC.

CSC (which after the Mergers is known as NeoStem Oncology, LLC) is a biopharmaceutical company with deep expertise in stem cell biology that is engaged in the development of therapies using a patient’s own, i.e., autologous, cells. To date, CSC’s development efforts have been directed at immunotherapies for cancer, regenerative medicine for motor neuron replacement and dermatology. CSC’s most advanced program is an immunotherapy, Melapuldencel-T, which uses patients’ own tumor cells to maximize the ability of their immune system to identify and eliminate the cancer initiating cells that are capable of reconstituting or developing new tumors (i.e., “cancer stem cells” or “replicating cells”). The focus of that program is the treatment of metastatic melanoma. As a result of encouraging Phase 2 data, CSC expects to initiate a Phase 3 clinical trial later in 2014, for which it has received Special Protocol Assessment (“SPA”) and Fast Track designation, as well as Orphan Drug designation. CSC maintains corporate offices and research facilities in Irvine, California.

Aggregate Merger Consideration

Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):


(1)	An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of cash in lieu of fractional shares) (the “Closing Merger Consideration”).

(2)

If payable after the Closing, certain milestone payments in an amount of up to $90 million in the aggregate, payable in shares of NeoStem common stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Receivables, Policy [Policy Text Block]

Accounts Receivable

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Other Intangible Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

3 Months Ended

Mar. 31, 2014

The Business [Abstract]

Subsidiary [Table Text Block]



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	90%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC (2)	100%	United States of America

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2014

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At March 31, 2014 and 2013, the Company excluded the following potentially dilutive securities:



	March 31,
	2014	2013
Stock Options	3,912,697	2,631,181
Warrants	4,491,028	5,501,055
Restricted Shares	175,731	35,500

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2014

Fair Value Measurements [Abstract]

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2014 by type of instrument (in thousands):



	Three Months Ended
	March 31, 2014
	Warrants		Acquisition-Related Contingent Consideration
Beginning liability balance	$	23.2	$	9,450.0
Change in fair value recorded in earnings	—		190.0
Ending liability balance	$	23.2	$	9,640.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]



	March 31, 2014
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	23.2
Acquisition-related contingent consideration	—		—		9,640.0

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill and Other Intangible Assets [Abstract]

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

The Company's intangible assets and related accumulated amortization as of March 31, 2014 and December 31, 2013 consisted of the following (in thousands):



		March 31, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(320.1	)	$	679.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,248.4		)	2,651.6		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(256.1		)	543.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	9,400.0		—			9,400.0		9,400.0		—			9,400.0
VSEL patent rights	19 years	669.0		(220.1		)	448.9		669.0		(211.3		)	457.7
Total Intangible Assets		$	15,769.0	$	(2,044.7	)	$	13,724.3	$	15,769.0	$	(1,893.4	)	$	13,875.6

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2014		2013
Cost of revenue	$	79.2	$	97.5
Research and development	27.1		8.8
Selling, general and administrative	45.0		45.0
Total	$	151.3	$	151.3

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	453.9
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	10,849.6
	$	13,724.3

Accrued Liabilities Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2014

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of March 31, 2014 and December 31, 2013 were as follows (in thousands):



	March 31, 2014		December 31, 2013
Salaries, employee benefits and related taxes	$	846.4	$	2,325.8
Professional fees	775.4		544.8
License Fees	200.0		500.0
Other	559.8		647.4
	$	2,381.6	$	4,018.0

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Shareholders’ Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2014:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0

Changes during the Period:
Granted	1,169,200		$	7.70				2,722		$	12.26
Exercised	(12,800	)	$	5.58				(250,000	)	$	5.10
Forfeited	(109,329	)	$	6.97				(100,108	)	$	70.00
Expired	(66,565	)	$	14.77				(59,852	)	$	57.76
Outstanding at March 31, 2014	3,912,697		$	10.22	7.4	$	1,896.7	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014 or expected to vest in the future	3,596,457		$	10.46	7.2	$	1,848.9	4,491,028		$	15.39	2.4	$	1,661.5
Vested at March 31, 2014	2,520,755		$	11.50	6.5	$	1,600.9	4,473,306		$	15.42	2.3	$	1,661.5

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

During the three months ended March 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		3,913
Value of Common Stock Purchase Warrants Issued	$	—	$	14.9

Restricted Stock [Table Text Block]

During the three months ended March 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2014		2013
Number of Restricted Stock Issued	329,698		177,492
Value of Restricted Stock Issued	$	2,511.7	$	1,127.9

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2014

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2014 and 2013 (in thousands):



	Three Months Ended March 31,
	2014		2013
Cost of goods sold	$	138.1	$	86.4
Research and development	476.8		217.4
Selling, general and administrative	3,278.7		1,914.7
Total share-based compensation expense	$	3,893.6	$	2,218.5

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	6,490.0	$	46.2	$	208.2
Expected weighted-average period in years of compensation cost to be recognized	5.62		1.30		0.35

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2014 and 2013 were as follows (dollars in thousands):



	Stock Options				Warrants
	Three Months Ended March 31,				Three Months Ended March 31,
	2014		2013		2014		2013
Total fair value of shares vested	$	1,927.4	$	1,305.0	$	8.7	$	43.8
Weighted average estimated fair value of shares granted	$	5.47	$	4.71	$	—	$	3.82

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2014 are as follows (in thousands):



Years ended	Operating Leases
2014	$	763.0
2015	840.4
2016	682.3
2017	386.9
2018	5.9
Total minimum lease payments	$	2,678.5

The Business (Details)			3 Months Ended
The Business (Details)	Jun. 19, 2012 segment	Jun. 18, 2012 segment	Mar. 31, 2014 USD ($)
The Company [Line Items]
Change in Ownership in Subsidiary			$ 0
Number of Reporting Segments \| segment	1	3
Noncontrolling Interest [Member]
The Company [Line Items]
Change in Ownership in Subsidiary			$ 86,617

The Business Principal of consolidation (Details)	3 Months Ended
The Business Principal of consolidation (Details)	Mar. 31, 2014
NeoStem, Inc. [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	Parent Company
NeoStem Therapies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
China Biopharmaceuticals Holdings, Inc. [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Suzhou Erye Pharmaceuticals Company Ltd. [Member] \| CHINA
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	51.00%
Progenitor Cell Therapy, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	1
Athelos Corporation [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	90.00%
Minority Interest Ownership Percentage By Parent [String]	0.90
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	1

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Clinical Services Reimbursement	$ 0.7	$ 0.4

Cash and Cash Equivalents (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 41,359,652	$ 46,133,759
Cash, FDIC Insured Amount	$ 700,000	$ 800,000

Inventories (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]
Inventory	$ 1,475,812	$ 1,270,223
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 1,600,000	$ 1,500,000

Loss Per Share (Details) - shares	3 Months Ended
Loss Per Share (Details) - shares	Mar. 31, 2014	Mar. 31, 2013
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,491,028	5,501,055
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,912,697	2,631,181
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	175,731	35,500

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 9,640,000	$ 9,450,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	23,200	23,200
Contingent Consideration Classified As Equity Fair Value Disclosure	$ 9,640,000	$ 9,450,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details)	3 Months Ended
	Mar. 31, 2014 USD ($)
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning liability balance	$ 23,200
Change in fair value recorded in earnings	0
Ending liability balance	23,200
contingent cosideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning liability balance	9,450,000
Change in fair value recorded in earnings	190,000
Ending liability balance	$ 9,640,000

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 15,769,000	$ 15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,044,700)	(1,893,400)
Finite-Lived Intangible Assets, Net	13,724,300	13,875,600
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(320,100)	(295,100)
Finite-Lived Intangible Assets, Net	$ 679,900	704,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,248,400)	(1,150,900)
Finite-Lived Intangible Assets, Net	$ 2,651,600	2,749,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(256,100)	(236,100)
Finite-Lived Intangible Assets, Net	$ 543,900	563,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R and D [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 9,400,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	$ 9,400,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	Indefinite
VSEL Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(220,100)	(211,300)
Finite-Lived Intangible Assets, Net	$ 448,900	$ 457,700
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 151,300	$ 151,300
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	79,200	97,500
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	27,100	8,800
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 45,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Goodwill [Abstract]
Goodwill	$ 11,117,770	$ 11,117,770
Future Amortization Expense, Year One	453,900
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Finite-Lived Intangible Assets, Amortization Expense, Year Five	605,200
Thereafter	10,849,600
Finite-Lived Intangible Assets, Future Amortization Expense	$ 13,724,300	$ 13,875,600

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 846.4	$ 2,325.8
Professional fees	775.4	544.8
Accrued Royalties, Current	200.0	500.0
Other	559.8	647.4
Accrued Liabilities	$ 2,381.6	$ 4,018.0

Debt (Details) - USD ($)			3 Months Ended
Debt (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Notes Payable			$ 1,700,000	$ 900,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Purchase of condominium units		$ 0
Debt Instrument, Frequency of Periodic Payment		monthly payments
Debt Instrument, Periodic Payment, Interest			5.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 2,400,000	2,500,000
Mortgage Loans on Real Estate, New Mortgage Loans		$ 3.1
PCT Allendale, LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			20,766
Mortgage Loan Repayble Amount within 12 months			128,300
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	6.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			741,800	$ 763,000
Mortgage Loan Repayble Amount within 12 months			$ 87,700
Mortgage Loans on Real Estate, New Mortgage Loans	$ 1,000,000
Debt Instrument, Period of Loan	124 months
Debt Instrument, Period of Fixed Interest Rate	64 months

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Net proceeds from issuance of common stock	$ 5,630,625	$ 2,730,262
Preferred Stock, Shares Outstanding	10,000		10,000
Fair Value, Inputs, Level 3 [Member]
Class of Stock [Line Items]
Warrant Derivative Liabilities	$ 23,200		$ 23,200

Shareholders' Equity Equity Issuances (Details) $ / shares in Units, $ in Millions		3 Months Ended
	Sep. 30, 2012 $ / shares	Mar. 31, 2014 USD ($) shares	Dec. 31, 2013 shares	Sep. 28, 2011 USD ($)
Class of Stock [Line Items]
Common Stock, Shares, Issued \| shares		28,593,410	27,196,537
Private Placement [Member]
Class of Stock [Line Items]
Investment Warrants, Exercise Price \| $ / shares	$ 5.10
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement \| $				$ 20.0
Term Of Agreement In Months				24
Discount Applied To Weighted Average Price		5.00%
Aegis Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Shares, Issued \| shares		800,000
Proceeds from Issuance of Common Stock Gross \| $		$ 5.6
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued \| shares		150,000
Purchase Commitment, Remaining Minimum Amount Committed \| $		$ 30.0

Shareholders' Equity Warrant Exercises (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Sep. 30, 2012	Mar. 31, 2014
Private Placement [Member]
Stock Options and Warrants [Line Items]
Investment Warrants, Exercise Price	$ 5.10
Warrant holder A [Member]
Stock Options and Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		250,000
Proceeds from Issuance of Warrants		$ 1.3

Shareholders' Equity Stock options and warrants (Details)	3 Months Ended
	Mar. 31, 2014 USD ($) $ / shares $ / warrant shares	Mar. 31, 2013 USD ($) shares	Dec. 31, 2013 $ / shares $ / warrant shares
Stock Options and Warrants [Line Items]
Stock Option Exercise	12,800
Stock Issued During Period, Shares, Other	0	3,913
Warrants Issued During Period, Value \| $	$ 0	$ 14,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 1,896,700
Common Stock Warrants, Shares	4,491,028		4,898,266
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	15.39		16.50
Weighted Average Remaining Contractual Term warrant outstanding	2 years 4 months 24 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 1,661,500
Warrants Granted	2,722
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 12.26
Warrants Exercised	(250,000)
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 5.10
Warrants Expired	(100,108)
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 70.00
Warrants Canceled	(59,852)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 57.76
Proceeds from Stock Options Exercised \| $	$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 1,848,900
shares, vested and expected to vest	4,491,028
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	15.39
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 1,661,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 1,600,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,473,306
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	15.42
weighted Average Remaining Contractual Term, warrants vested	2 years 3 months 18 days
Aggregate Intrinsic Value, Warrants vested \| $	$ 1,661,500
Warrants
Stock Options and Warrants [Line Items]
Weighted average estimated fair value of shares granted \| $ / shares	$ 0.00		$ 3.82
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,912,697		2,932,191
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 10.22		$ 11.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,169,200
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 7.70
Stock Options Exercised	(12,800)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 5.58
Stock Options Expired	(109,329)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	$ 6.97
Stock Options Forfeited	(66,565)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 14.77
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,596,457
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 10.46
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 2 months 9 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,520,755
Weighted average estimated fair value of shares granted \| $ / shares	$ 11.50
Options, Vested, weighted Average Remaining Contractual Term	6 years 5 months 27 days
Minimum [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares	$ 5.20
Maximum [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares	$ 6.20

Shareholders' Equity Restricted Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	329,698	177,492
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 2,511,700	$ 1,127,900
weighted average estimated fair value of restricted stock	$ 7.62	$ 6.35

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 3,893,600	$ 2,218,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 6,490,000
Expected weighted-average period in years of compensation cost to be recognized	5 years 7 months 13 days
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 46,200
Expected weighted-average period in years of compensation cost to be recognized	1 year 3 months 18 days
Total fair value of shares vested	$ 8,700	43,800
Weighted average estimated fair value of shares granted	$ 0.00		$ 3.82
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 5.47		$ 4.71
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 208,200
Expected weighted-average period in years of compensation cost to be recognized	4 months 6 days
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 138,100	86,400
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	476,800	217,400
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	3,278,700	1,914,700
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 1,927,400	$ 1,305,000

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 110,600,000
Deferred Tax Liabilities, Net, Noncurrent	$ 4,426,635	$ 4,379,226

Commitments and Contingencies (Details) - USD ($)	3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Mar. 31, 2014	Mar. 31, 2013
Operating Leases, Future Minimum Payments Due [Abstract]
2013	$ 763,000
2014	840,400
2015	682,300
2016	386,900
Thereafter	5,900
Total minimum lease payments	2,678,500
Operating Leases, Rent Expense	$ 200,000	$ 300,000

Subsequent Events (Details) - USD ($)	3 Months Ended
Subsequent Events (Details) - USD ($)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,473,306
Common Stock, Par Value	$ 0.001		$ 0.001
Common Stock, Shares, Issued	28,593,410		27,196,537
Proceeds from exercise of warrants	$ 1,275,000	$ 105,881
Proceeds from Stock Options Exercised	$ 71,360	$ 0
Aegis Capital Purchase Agreement [Member]
Subsequent Event [Line Items]
Shares, Issued	800,000
Proceeds from Issuance of Common Stock Gross	$ 5,600,000